A luciferase-based high-throughput three-dimensional tumor spheroid model identifies a renieramycin T derivative with anti-cancer stem cell activity in non-small cell lung cancer

Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to therapeutic resistance and tumor recurrence. In non-small cell lung cancer (NSCLC), cancer stem cells (CSCs) have emerged as key contributors to tumor persistence and progression. However, accelerated CSC-targeted drug discovery is limited by the lack of scalable and quantitative screening systems capable of capturing stemness-associated phenotypes. Conventional two-dimensional (2D) assays often fail to reflect the architectural and molecular complexity of CSC-enriched tumor populations. Here, we report the establishment of a luciferase-based three-dimensional (3D) NSCLC spheroid platform integrating CSC-like enrichment with a high-throughput quantitative readout. The luminescent signal strongly correlated with spheroid burden and viable cell content. Compared with 2D monolayers, 3D NSCLC spheroids exhibited elevated expression of pluripotency-associated factors, including OCT4, NANOG, and SOX2, and CSC-associated markers, namely CD44, ALDH1A1, and ABCG2, supporting the enrichment of CSC-like subpopulations. As a proof-of-concept, screening of renieramycin T right-half derivatives identified DH_18 as a lead compound in the established 3D NSCLC spheroid model, exhibiting greater potency than DH_19, accompanied by increased apoptosis and reduced CSC-associated proteins in follow-up experimental validation. Integrated network pharmacology incorporating enrichment and protein-protein interaction analyses further mapped DH_18-NSCLC targets to lung CSC-associated networks and pathways related to stemness and aggressive tumor phenotypes, reinforcing the biological relevance of the 3D screening context. Collectively, these findings present a quantitative and scalable 3D NSCLC spheroid platform suitable for CSC-targeted drug screening and nominate DH_18 as a candidate compound with potential activity against stemness-linked molecular networks.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-09-01
DOI
https://doi.org/10.1016/j.biopha.2026.119898
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A luciferase-based high-throughput three-dimensional tumor spheroid model identifies a renieramycin T derivative with anti-cancer stem cell activity in non-small cell lung cancer

Pithi Chanvorachote, Surapol Issaragrisil, Napachai Rodboon, Masashi Yokoya et al.
Biomedicine & Pharmacotherapy
Cancer Cells and Metastasis
article

A luciferase-based high-throughput three-dimensional tumor spheroid model identifies a renieramycin T derivative with anti-cancer stem cell activity in non-small cell lung cancer

Pithi Chanvorachote, Surapol Issaragrisil, Napachai Rodboon, Masashi Yokoya, Sudjit Luanpitpong, Supasorn Chanthateyanonth, Parinya Samart, Nitit Charoenvitayavorakul, Tatsuki Yamada
article en

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to therapeutic resistance and tumor recurrence. In non-small cell lung cancer (NSCLC), cancer stem cells (CSCs) have emerged as key contributors to tumor persistence and progression. However, accelerated CSC-targeted drug discovery is limited by the lack of scalable and quantitative screening systems capable of capturing stemness-associated phenotypes. Conventional two-dimensional (2D) assays often fail to reflect the architectural and molecular complexity of CSC-enriched tumor populations. Here, we report the establishment of a luciferase-based three-dimensional (3D) NSCLC spheroid platform integrating CSC-like enrichment with a high-throughput quantitative readout. The luminescent signal strongly correlated with spheroid burden and viable cell content. Compared with 2D monolayers, 3D NSCLC spheroids exhibited elevated expression of pluripotency-associated factors, including OCT4, NANOG, and SOX2, and CSC-associated markers, namely CD44, ALDH1A1, and ABCG2, supporting the enrichment of CSC-like subpopulations. As a proof-of-concept, screening of renieramycin T right-half derivatives identified DH_18 as a lead compound in the established 3D NSCLC spheroid model, exhibiting greater potency than DH_19, accompanied by increased apoptosis and reduced CSC-associated proteins in follow-up experimental validation. Integrated network pharmacology incorporating enrichment and protein-protein interaction analyses further mapped DH_18-NSCLC targets to lung CSC-associated networks and pathways related to stemness and aggressive tumor phenotypes, reinforcing the biological relevance of the 3D screening context. Collectively, these findings present a quantitative and scalable 3D NSCLC spheroid platform suitable for CSC-targeted drug screening and nominate DH_18 as a candidate compound with potential activity against stemness-linked molecular networks.

Biomedicine & PharmacotherapyVol. 203
Siriraj Hospital (TH), Chulalongkorn University (TH), Meiji Pharmaceutical University (JP), Mahidol University (TH), Bangkok Hospital (TH)
Chulalongkorn University, Mahidol University, National Research Council of Thailand
Good health and well-being
Openalex Percentile: Top 14%
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.